H1N1 influenza vaccine: Global access for a global problem

Abstract

More than 90% of the world’s capacity to manufacture influenza vaccines is concentrated in Europe and North America. Pressure to protect one’s own citizens will be intense during any pandemic. If any of the countries where these plants are located choose to nationalize the companies making the